Abpro Holdings, Inc. — Investor Relations & Filings
Filings indexed
242
across all filing types
Latest filing
2026-05-20
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
ABP
Abpro Holdings, Inc. is a clinical-stage biotechnology company that develops next-generation antibody therapeutics. The company focuses on creating novel antibody constructs for challenging and high-value targets in immuno-oncology and ophthalmology. Its pipeline includes therapies targeting various cancers such as HER2-positive (HER2+) breast and gastric cancers, as well as non-HER2+ gastric, colorectal, and liver cancers. In ophthalmology, Abpro is developing treatments for conditions like wet age-related macular degeneration. The company utilizes its proprietary DiversImmune™ platform to engineer and discover its therapeutic candidates, aiming to address severe and life-threatening diseases with significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-20 | English | |
| 10-K - Abpro Holdings, Inc. (0001893219) (Filer) | 2026-04-15 | English | |
| 8-K - ABPRO HOLDINGS, INC. (0001893219) (Filer) | 2026-02-20 | English | |
| 8-K Filing | 2026-02-11 | English | |
| 8-K Filing | 2026-02-03 | English | |
| CURRENT REPORT | 2026-01-23 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 46694579 | QUARTERLY REPORT | 2026-05-20 | English | ||
| 34613638 | 10-K - Abpro Holdings, Inc. (0001893219) (Filer) | 2026-04-15 | English | ||
| 32900395 | 8-K - ABPRO HOLDINGS, INC. (0001893219) (Filer) | 2026-02-20 | English | ||
| 32182522 | 8-K Filing | 2026-02-11 | English | ||
| 32182442 | 8-K Filing | 2026-02-03 | English | ||
| 13546405 | CURRENT REPORT | 2026-01-23 | English | ||
| 13546408 | CURRENT REPORT | 2026-01-06 | English | ||
|
2025
8 filings
| |||||
| 13546406 | CURRENT REPORT | 2025-12-15 | English | ||
| 13546407 | CURRENT REPORT | 2025-12-09 | English | ||
| 13546413 | Regulatory Filings 2025 | 2025-12-03 | English | ||
| 13546417 | AMENDMENT NO. 1 TO FORM S-1 | 2025-11-28 | English | ||
| 13546418 | PROSPECTUS SUPPLEMENT | 2025-11-17 | English | ||
| 13546420 | QUARTERLY REPORT | 2025-11-14 | English | ||
| 13546480 | REGISTRATION STATEMENT | 2025-11-07 | English | ||
| 13546499 | AMENDMENT NO. 1 TO FORM 8-K | 2025-11-04 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
Abpro Holdings, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34955/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34955 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34955 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34955 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34955}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abpro Holdings, Inc. (id: 34955)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.